WS #16018
The biotech sector is seeing targeted bullish catalysts, highlighted by Eli Lilly's weight-loss pill receiving backing from EU regulators. This regulatory win reinforces the strong demand trajectory for GLP-1 therapies. Concurrently, analyst upgrades for Abbott Laboratories suggest that defensive healthcare names are also attracting capital as investors seek stability amidst the broader market volatility.
Biotech & Healthcare Regulatory Wins
The biotech sector is seeing targeted bullish catalysts, highlighted by Eli Lilly's weight-loss pill receiving backing from EU regulators. This regulatory win reinforces the strong demand trajectory for GLP-1 therapies. Concurrently, analyst upgrades for Abbott Laboratories suggest that defensive healthcare names are also attracting capital as investors seek stability amidst the broader market volatility.